ICU Management & Practice, ICU Volume 7 - Issue 3 - Autumn 2007

LiDCO, the UK based, AIM-quoted cardiovascular monitoring company, announced that it has received confirmation of the approval of its US Patent application for a new method and apparatus for optimally adjusting a biventricular pacemaker – used for the treatment of congestive heart failure (CHF). The method involves the measurementof changes in certain haemodynamic parameters (arterial pulse pressure and stroke volume) that have been shown to reflect improvements in the heart’s pumping action (ventricular performance). Using the LiDCOplus Monitor these parameters are measured minimally invasively and beatto- beat.


www.lidco.com

«« New ‘Robust’ Treatment for Stroke Uses Genetic Material From Bone Marrow


Your Eyes May Hold Clues to Stroke Risk »»